Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03722706 · ClinicalTrials.gov registry record · NA

Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook

A NA study of Dermatitis, Atopic, sponsored by Boston Children's Hospital.

Completed
Registry status
NA
Development phase
246
Enrollment target
1
Study location

NCT03722706: Completed NA study of Dermatitis, Atopic, sponsored by Boston Children's Hospital.

NCT03722706 is a NA study of Dermatitis, Atopic that has completed, run by Boston Children's Hospital. The registered enrollment target is 246 participants, below the 389-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03722706, a NA study of Dermatitis, Atopic, has completed, sponsored by Boston Children's Hospital.

COMPLETED
Registry status
NA
Development phase
246 participants
Enrollment target
1
Study location

Study Summary

The objective of this research is to evaluate the effectiveness of an educational handbook for parents of children with atopic dermatitis (AD) in improving clinical outcomes for pediatric patients with AD and their parents. The handbook was developed by an interdisciplinary team of healthcare providers to facilitate therapeutic patient education as a routine component of care for pediatric patients with atopic dermatitis (AD). Patient education is an important element of practice management guidelines for AD, particularly given complex treatment plans and high rates of non-adherence in this population. Parents of children with AD will be randomized into either the handbook arm (handbook provided as an adjunct to standard AD management with a healthcare provider at Boston Children's Hospital) or the control arm (standard management alone). Participants will complete study measures at two time points: baseline (prior to a clinic visit appointment for AD care at Boston Children's Hospital), and 3-month follow-up. Data will be analyzed for change on study outcome measures (AD symptoms, AD severity, quality of life) and satisfaction with the handbook.

Primary Outcome

parent-report of child's atopic dermatitis symptoms

Conditions Studied

Interventions

  • OTHER Educational handbook

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 246 participants
Start Date 2019-02-26
Est. Completion 2020-03-30
Phase NA
Boston Children's Hospital

462 total trials

What the finished NCT03722706 record still lists

NCT03722706 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, below the 389-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (37% lower).

The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 1 intervention - of which Educational handbook is the first listed.

NCT03722706 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03722706 about?

NCT03722706 is a clinical study titled "Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook". The objective of this research is to evaluate the effectiveness of an educational handbook for parents of children with atopic dermatitis (AD) in improving clinical outcomes for pediatric patients with AD and their parents. The handbook was developed by an interdisciplinary team of healthcare provid...

What is the current status of trial NCT03722706?

This trial is currently completed. It is a NA study. The enrollment target is 246 participants. The study started on 2019-02-26. Estimated completion is 2020-03-30.

What conditions does trial NCT03722706 study?

This clinical trial studies the following conditions: Dermatitis, Atopic.

What interventions are being tested in trial NCT03722706?

The interventions under investigation include: Educational handbook (OTHER).

Who is sponsoring clinical trial NCT03722706?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03722706 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dermatitis, Atopic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03722706's enrollment target sits among peer trials

246 14th of 29 higher than 16 of 29 other Dermatitis, Atopic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04973605 · 246 participants · Phase 1

    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

  • NCT06395168 · 246 participants · NA

    Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination

  • NCT07048769 · 246 participants · Phase 4

    Paracervical Block for Pain Reduction in Saline Infusion Sonograms

  • NCT07176650 · 246 participants · Phase 1

    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03722706, the US trial registry maintained by the National Library of Medicine. NCT03722706 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.